Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -52.25% is in line with its 5-year average of -55.50%, near the high end of its 5-year range (-142.92%–-16.62%).
25.13% below its 12-month average of -41.76%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -17.96%.
RETURN ON ASSETS (ROA)
-52.25%
RETURN ON ASSETS (ROA) AVG TTM
-41.76%
RETURN ON ASSETS (ROA) AVG 3Y
-70.33%
RETURN ON ASSETS (ROA) AVG 5Y
-55.50%
RETURN ON ASSETS (ROA) AVG 10Y
-43.82%
RETURN ON ASSETS (ROA) AVG 15Y
-25.78%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-25.13%
CURRENT VS 3Y AVG
+25.70%
CURRENT VS 5Y AVG
+5.86%
CURRENT VS 10Y AVG
-19.25%
CURRENT VS 15Y AVG
-102.70%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.05%
median of 558 covered companies
CURRENT VS SECTOR MEDIAN
-86.31%
vs the sector median at left
Dyne Therapeutics, Inc.
Market Cap
$2.83B
Return on Assets (ROA)
-52.25%
TTM Avg
-41.76%
3Y Avg
-70.33%
5Y Avg
-55.50%
Market Cap
$2.83B
Return on Assets (ROA)
1.56%
TTM Avg
-4.54%
3Y Avg
-5.50%
5Y Avg
-3.43%
Market Cap
$2.83B
Return on Assets (ROA)
10.36%
TTM Avg
11.11%
3Y Avg
1.40%
5Y Avg
-7.68%
Market Cap
$2.74B
Return on Assets (ROA)
-23.93%
TTM Avg
-22.82%
3Y Avg
-35.57%
5Y Avg
-35.57%
Market Cap
$2.72B
Return on Assets (ROA)
13.04%
TTM Avg
11.11%
3Y Avg
0.70%
5Y Avg
-8.32%
Market Cap
$2.69B
Return on Assets (ROA)
-20.31%
TTM Avg
-7.83%
3Y Avg
-2.64%
5Y Avg
-2.82%
Market Cap
$2.66B
Return on Assets (ROA)
-6.16%
TTM Avg
-19.77%
3Y Avg
-17.54%
5Y Avg
-23.06%
Market Cap
$3.04B
Return on Assets (ROA)
-57.49%
TTM Avg
-99.67%
3Y Avg
-60.13%
5Y Avg
-103.92%
Market Cap
$3.10B
Return on Assets (ROA)
5.84%
TTM Avg
-21.93%
3Y Avg
-47.49%
5Y Avg
-47.67%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | $2.83B | -52.25% | -41.76% | -70.33% | -55.50% |
| AtriCure, Inc. (ATRC)vs › | $2.83B | 1.56% | -4.54% | -5.50% | -3.43% |
| TransMedics Group, Inc. (TMDX)vs › | $2.83B | 10.36% | 11.11% | 1.40% | -7.68% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.74B | -23.93% | -22.82% | -35.57% | -35.57% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.72B | 13.04% | 11.11% | 0.70% | -8.32% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | -20.31% | -7.83% | -2.64% | -2.82% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.66B | -6.16% | -19.77% | -17.54% | -23.06% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.04B | -57.49% | -99.67% | -60.13% | -103.92% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.10B | 5.84% | -21.93% | -47.49% | -47.67% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.11B | -11.64% | -24.55% | -30.16% | -27.23% |
ROA
-52.3%
ROE
-74.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -37.59% |
| 2024-12-31 | -45.92% |
| 2023-12-31 | -142.92% |
| 2022-12-31 | -54.88% |
| 2021-12-31 | -35.07% |
| 2020-12-31 | -16.62% |
| 2019-12-31 | -82.36% |
| 2018-12-31 | -58.19% |
| 2017-12-31 | 0.65% |
| 2016-12-31 | -9.50% |
| 2015-12-31 | 0.43% |
| 2014-12-31 | -0.60% |
| 2013-12-31 | -6.73% |
| 2012-12-31 | 1.92% |
| 2011-12-31 | -39.86% |
| 2010-12-31 | -2.34% |
| 2009-12-31 | -11.52% |
| 2008-12-31 | 1.22% |
| 2007-12-31 | 2.00% |
